Journal
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM
Volume 18, Issue 2, Pages 181-198Publisher
ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
DOI: 10.1080/17446651.2023.2185221
Keywords
Aggressive pituitary tumors; discontinuation; Follow-up; pituitary carcinoma; temozolomide
Categories
Ask authors/readers for more resources
Despite multimodal treatment, pituitary adenomas can still show a tendency to grow. Temozolomide (TMZ) has been used for the treatment of aggressive pituitary tumors in the past 15 years. The use of TMZ requires a careful balance of different expertise, especially in terms of selection criteria.
IntroductionPituitary adenomas can show a tendency to grow, despite multimodal treatment. Temozolomide (TMZ) has been used in the last 15 years in patients with aggressive pituitary tumors. TMZ requires a careful balance of different expertise, especially for selection criteria.Areas coveredWe conducted: (1) a systematic review of the published literature from 2006 to 2022, collecting only cases with a complete description of patient follow-up after TMZ discontinuation; (2) a description of all patients with aggressive pituitary adenoma or carcinoma treated in Padua (Italy).Expert opinionThere is considerable heterogeneity in the literature: TMZ cycles duration ranged from 3 to 47 months; the follow-up time after TMZ discontinuation ranged from 4 to 91 months (mean 24 months, median 18 months), at least a stable disease has been reported in 75% of patients after a mean 13 months (range 3-47 months, median 10 months). The Padua (Italy) cohort reflects the literature. Future directions to explore are to understand the pathophysiological mechanism of TMZ resistance escape, to develop predicting factors to TMZ treatment (especially through the delineation of the underlying transformation processes), and to further expand the therapeutic applications of TMZ (as neoadjuvant, combined with radiotherapy).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available